US4116951A
(en)
*
|
1977-04-22 |
1978-09-26 |
Hoffmann-La Roche Inc. |
[Asn2 ]-thymosin α1 and analogs thereof
|
US4680276A
(en)
*
|
1977-05-25 |
1987-07-14 |
Institut National De La Sante Et De La Recherche Medicale |
Metal polypeptides
|
US4264571A
(en)
*
|
1979-01-22 |
1981-04-28 |
George Washington University |
Radioimmunoassay of thymosin α1
|
US4297276A
(en)
*
|
1979-03-23 |
1981-10-27 |
Hoffman-La Roche Inc. |
Thymosin beta 3 and beta 4
|
US4261886A
(en)
*
|
1980-03-13 |
1981-04-14 |
Ortho Pharmaceutical Corporation |
Peptides having thymopoietin-like activity
|
DE2919592A1
(de)
*
|
1979-05-15 |
1981-01-15 |
Max Planck Gesellschaft |
Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
|
EP0033384B1
(fr)
*
|
1980-01-18 |
1984-02-15 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Médicaments contenant des fragments de thymosine-alpha-1, leur activité immunostimulante, et fragments de thymosine-alpha-1
|
JPS56138154A
(en)
*
|
1980-02-28 |
1981-10-28 |
Genentech Inc |
Desacetylthymosin-alpha-1 and manufacture
|
US4361673A
(en)
*
|
1980-09-19 |
1982-11-30 |
American Home Products Corporation |
Polypeptide compositions
|
SE448605B
(sv)
*
|
1980-10-27 |
1987-03-09 |
Vtoroi Mo G Med I Imen |
Terapeutiskt preparat for reglering av t-immunsystemet och forfarande for framstellning derav
|
JPS57110196A
(en)
*
|
1980-10-30 |
1982-07-08 |
Hoffmann La Roche |
Preparation of thimocin alpha 1
|
US4444757A
(en)
*
|
1981-11-16 |
1984-04-24 |
Research Corporation |
Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
|
US4388234A
(en)
*
|
1981-12-28 |
1983-06-14 |
Hoffmann-La Roche Inc. |
Peptide isolation
|
DE3230151A1
(de)
*
|
1982-08-13 |
1984-02-16 |
Hoechst Ag, 6230 Frankfurt |
Neues polypeptid mit wirkung auf das immunsystem, verfahren zu seiner isolierung und reinigung, seine verwendung, dieses enthaltende mittel sowie seine spaltprodukte, deren verwendung und diese enthaltende mittel
|
US4504415A
(en)
*
|
1983-04-04 |
1985-03-12 |
Hoffman-La Roche Inc. |
Synthesis of thymosin α1 and desacetyl thymosin α1
|
US4517119A
(en)
*
|
1983-04-04 |
1985-05-14 |
Hoffmann-La Roche Inc. |
Synthesis of thymosin α1
|
US4543340A
(en)
*
|
1983-04-07 |
1985-09-24 |
George Washington University |
Radioimmunoassay of thymosin β4
|
US4614731A
(en)
*
|
1983-09-15 |
1986-09-30 |
Hoffmann-La Roche Inc. |
Peptide having immunopotentiating activity similar to thymosin alpha1
|
US4621135A
(en)
*
|
1983-12-08 |
1986-11-04 |
Yeda Research & Development Company, Ltd. |
Novel THF compositions
|
US4983387A
(en)
*
|
1986-05-19 |
1991-01-08 |
Viral Technologies Inc. |
HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
|
US4777239A
(en)
*
|
1986-07-10 |
1988-10-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Diagnostic peptides of human papilloma virus
|
US5728680A
(en)
|
1987-12-30 |
1998-03-17 |
Cytoven J.V. |
Methods for normalizing numbers of lymphocytes
|
US5807830A
(en)
*
|
1987-12-30 |
1998-09-15 |
Cytoven J.V. |
Method for treatment of purulent inflammatory diseases
|
US5811399A
(en)
*
|
1988-12-14 |
1998-09-22 |
Cytran, Inc. |
Pharmaceutical dipeptide compositions and methods of use thereof: immunodepressants
|
US5770576A
(en)
*
|
1989-08-30 |
1998-06-23 |
Cytran, Inc. |
Pharmaceutical dipeptide compositions and methods of use thereof: systemic toxicity
|
EP0570478A4
(en)
*
|
1991-02-04 |
1994-08-17 |
Univ George Washington |
Mb-40 peptide that enhances the production of interleukin-1 and modulates age-associated immune response
|
US5273963A
(en)
*
|
1991-03-29 |
1993-12-28 |
The George Washington University |
Compositions and methods for treating small cell and nonsmall cell lung cancers
|
US6066622A
(en)
|
1991-10-28 |
2000-05-23 |
Cytran, Inc. |
Immunomodulating peptides and methods of use
|
US6100380A
(en)
*
|
1991-10-28 |
2000-08-08 |
Cytran, Inc. |
Immunomodulating peptides and methods of use
|
EP0728010A4
(fr)
*
|
1992-02-06 |
1997-10-01 |
Sciclone Pharmaceuticals |
Methode de traitement de porteurs de l'hepatite b presentant un etat pathologique minime
|
US5308833A
(en)
*
|
1992-02-06 |
1994-05-03 |
Sciclone Pharmaceuticals |
Method for treating hepatitis B carriers with minimal disease
|
CN1058500C
(zh)
*
|
1993-02-03 |
2000-11-15 |
施塞克龙药品公司 |
胸腺素α-1衍生物
|
AU6359594A
(en)
*
|
1993-03-04 |
1994-09-26 |
Cytoven International N.V. |
Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
|
US6200952B1
(en)
*
|
1993-06-02 |
2001-03-13 |
Sciclone Pharmaceuticals, Inc. |
Combination therapy method for treating chronic hepatitis B
|
WO1995009647A1
(fr)
*
|
1993-10-07 |
1995-04-13 |
The George Washington University Medical Center |
PROCEDE DE TRAITEMENT DU CHOC SEPTIQUE à L'AIDE DE THYMOSINE-α¿1?
|
TW252045B
(fr)
*
|
1993-10-07 |
1995-07-21 |
Allan L Goldstein |
|
WO1995012405A1
(fr)
*
|
1993-11-05 |
1995-05-11 |
Alpha 1 Biomedicals, Inc. |
Methode et composition pour le traitement de patients souffrant d'une maladie hepatique decompensee
|
US6262230B1
(en)
|
1994-01-28 |
2001-07-17 |
Sciclone Pharmaceuticals Inc. |
Analogs of thymosin α1
|
JP3853384B2
(ja)
*
|
1994-09-09 |
2006-12-06 |
株式会社三菱化学ヤトロン |
抗サイモシンα1モノクローナル抗体産生ハイブリドーマ
|
US5632983A
(en)
|
1994-11-17 |
1997-05-27 |
University Of South Florida |
Method for treating secondary immunodeficiency
|
AU6164898A
(en)
*
|
1997-02-18 |
1998-09-08 |
Sciclone Pharmaceuticals, Inc. |
Use of thymosin alpha 1 for the manufacture of a medicament for promoting stem cell development
|
US20070025958A1
(en)
|
2000-10-27 |
2007-02-01 |
Hadden John W |
Vaccine immunotherapy
|
US20070154399A1
(en)
*
|
2000-10-27 |
2007-07-05 |
Hadden John W |
Immunotherapy for immune suppressed patients
|
JP2004521867A
(ja)
*
|
2000-10-27 |
2004-07-22 |
イミュノ−アールエックス, インコーポレイテッド |
免疫抑制された患者のためのワクチン免疫療法
|
PL370453A1
(en)
*
|
2001-10-26 |
2005-05-30 |
Rhode Island Hospital |
Thymosin augmentation of genetic immunization
|
UA78726C2
(en)
*
|
2001-11-01 |
2007-04-25 |
Sciclone Pharmaceuticals Inc |
Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
|
UA77999C2
(en)
*
|
2001-12-10 |
2007-02-15 |
|
Thymosin-alpha 1 for treatment of malignant glioblastoma
|
CA2506893A1
(fr)
|
2002-11-25 |
2004-06-10 |
Sciclone Pharmaceuticals, Inc. |
Procedes de protection contre des dommages dus a un rayonnement, faisant appel a la thymosine alpha
|
NZ542900A
(en)
|
2003-03-28 |
2007-06-29 |
Sciclone Pharmaceuticals Inc |
Treatment of aspergillus infections with thymosin alpha 1
|
US20100311656A1
(en)
*
|
2003-04-23 |
2010-12-09 |
Sciclone Pharmaceuticals, Inc. |
Treatment or prevention of respiratory viral infections with alpha thymosin peptides
|
CN1822850A
(zh)
*
|
2003-07-18 |
2006-08-23 |
雷根内克斯生物制药有限公司 |
由放射线照射引起的损伤的治疗或预防
|
WO2005115341A2
(fr)
*
|
2004-05-27 |
2005-12-08 |
Advanced Bionutrition Corporation |
Microparticules pour administration orale
|
ITRM20060583A1
(it)
*
|
2006-10-27 |
2008-04-28 |
Francesco Bistoni |
Uso della timosina alfa 1 per la preparazione di un medicamento per la prevenzione e la cura delle allergie
|
WO2009070639A1
(fr)
|
2007-11-28 |
2009-06-04 |
Irx Therapeutics, Inc. |
Méthode propre à accroître un effet immunologique
|
US8716012B2
(en)
*
|
2009-05-08 |
2014-05-06 |
Sciclone Pharmaceuticals, Inc. |
Alpha thymosin peptides as vaccine enhancers
|
DK2429585T3
(en)
|
2009-05-15 |
2018-07-30 |
Irx Therapeutics Inc |
VACCINE IMMUNOTHERAPY
|
EP2510106B1
(fr)
|
2009-12-08 |
2018-02-14 |
IRX Therapeutics, Inc. |
Méthode d'inversion de la suppression immunitaire des cellules de langerhans
|
US20130296223A1
(en)
|
2012-03-30 |
2013-11-07 |
Sciclone Pharmaceuticals, Inc. |
Use of thymosin alpha for the treatment of sepsis
|
GB201621732D0
(en)
*
|
2016-12-20 |
2017-02-01 |
Agricultural Research Council |
A multi-epitope dna vaccine for heartwater
|